Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | First line immunotherapy/chemotherapy in HER2- gastric cancer in Japan

Kensei Yamaguchi, MD, Cancer Institute Hospital of JFCR, Tokyo, Japan, discusses first-line chemotherapy and immunotherapy in HER2-negative gastric cancer in Japan and the patients that benefit from either line of treatment. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).